Miricor Enterprises Holdings Limited Overview
Miricor is a small-cap Hong Kong operator of premium non-surgical medical aesthetic and wellness-beauty centres. It is founded, chaired and run by former actress Gigi Lai (Lai Ka Yee Gigi), whose personal brand is central to customer acquisition.
The group runs five treatment centres in Hong Kong's core districts:
-
three CosMax+ medical aesthetic centres (Causeway Bay, Central and Tsim Sha Tsui);
-
two VITAE wellness-beauty centres.
It also sells the Swiss-formulated XOVĒ skincare line through four Hong Kong mall stores and online/mainland channels.
The business is overwhelmingly service-led. Treatment services were 86.9% of FY2025 revenue and medical aesthetics about 89% of FY2026 revenue. It is funded by prepaid treatment packages, with about HK$184m of contract liabilities.
After a failed mainland skincare push in FY2023–FY2024, management retrenched. Since FY2025 it has run a cost-led profit recovery. The company is now debt-free with HK$190m of cash and restored a dividend in FY2026. It is a niche, founder-controlled, cash-rich but shrinking-revenue player in a consolidating, increasingly regulated Hong Kong aesthetics market.
Company's own description. In its filings the group describes itself as principally engaged in two things [RA25; AR25]:
-
providing non-surgical medical aesthetic and wellness beauty services in Hong Kong and Mainland China;
-
selling skincare products.
It reports a single operating segment, "non-surgical medical aesthetic and wellness beauty services". Resources are managed on a unified basis, so no segment P&L is presented. In its corporate governance statement, the company's stated purpose is to become a "powerhouse of Women's Love Brands". It says it does this through customised medical aesthetic and wellness treatments, skincare and cosmetic products, and health supplements [AR25].
Revenue model. Revenue is recognised in four contract-revenue lines [RA25]:
The economic model is a prepaid-package model. Customers purchase treatment courses in advance and revenue is recognised as treatments are consumed. Contract liabilities and deferred revenue were HK$183.7m at 31 March 2025, about 46% of annual revenue [RA25]. This prepayment float largely explains why the group holds substantial cash despite thin profitability. There is no material subscription or licensing income. The group does own its trademarks (XOVĒ, VITAE, CosMax+).
Value-chain position. Miricor sits at the consumer-facing end of the aesthetics value chain:
Upstream: it buys devices, injectables and consumables from third-party manufacturers and distributors. Cost of inventories and consumables was HK$50.4m in FY2025 [RA25].
Doctor-led delivery: treatments are delivered in branded clinics. The company states that all equipment and treatments are clinically evaluated by professional doctors [AR25].
Own skincare brand: XOVĒ is outsourced in formulation, described as backed by a Swiss skincare expert team.
Customer types. The customers are individual retail consumers, predominantly female. The FY2025 MD&A identifies the 20–40 age group as the industry's core demographic, with a rising male share [AR25]. No single customer exceeds 10% of revenue [RA25]. Corporate customers exist but are minor.
End-markets.
-
Hong Kong non-surgical medical aesthetics, about 99% of FY2025 revenue.
-
Hong Kong wellness-beauty services.
-
Premium skincare retail in Hong Kong and, marginally, Mainland China. Mainland revenue was HK$2.8m in FY2025, down from HK$43.4m in FY2024 [RA25].
Independent characterisation. Miricor is best understood as a founder-branded, Hong Kong-centric clinic chain with a capital-light skincare adjunct.
Its competitive moat rests on four things:
-
the celebrity founder's brand equity;
-
prime-location centres;
-
a stock of prepaid customer relationships;
-
a regulatory/medical-safety positioning, reinforced by having former Director of Health Dr. Lam Ping Yan on the board.
Its key weakness is scale. Revenue of HK$362m is roughly 38% of the largest listed Hong Kong peer, Perfect Medical. The group also has a demonstrated inability to make the skincare-retail and mainland expansion strategy pay.
Strategy
Stated strategy (themes from AR25 and the FY2026 results). Management frames strategy around four "core powers": Branding, Customer-Focused, Professionalism and Management Optimisation (品牌力、客戶力、專業力、管理力) [AR25].
-
Branding: strengthen brand influence and recognition; develop new consumer segments beyond the existing base; use digital marketing and precise customer insights.
-
Customer-focused: treat existing customers as the core asset; segment retention strategies by spending pattern; design campaigns to deepen brand identification. The loyalty programme was revamped in FY2025.
-
Professionalism: continuous staff training; introduce innovative, personalised high-end treatments.
-
Management optimisation: optimise the sales network (i.e., close or relocate weak stores); streamline processes; strengthen digital management systems.
FY2026 additions [FY26-S].
Regulatory positioning: Management expects Hong Kong's stricter regulation of medical devices and practitioners to raise entry barriers, eliminate non-compliant operators and shift share to compliant leaders. It is positioning Miricor as a beneficiary.
Digital transformation: Continued investment in digital operations for customer targeting, conversion and security.
Asset allocation: Systematic introduction of compliant, high-technology-barrier equipment.
Omni-channel skincare: "Online-offline omni-channel integration" for XOVĒ, creating a closed-loop ecosystem for engagement and cross-selling between clinic and retail customers.
Cross-brand synergies: Between CosMax+ and VITAE: store-network efficiency and customer lifecycle management to maximise value per customer.
Initiatives announced in the last 24 months.
Medium-term financial targets and guidance: none publicly disclosed. The company has no stated payout ratio (its dividend policy explicitly has none) [AR25].
Products & Services
Miricor does not publish a priced treatment menu in its filings. Pricing is not publicly disclosed in regulatory documents; retail prices appear only on brand websites and promotions. The catalogue below reflects what has been disclosed in filings and press releases.
CosMax+ (medical aesthetics)
| Offering | Description / capabilities | Target customer | Year / status | Pricing model |
|---|---|---|---|---|
| Injectables (botulinum toxin, hyaluronic acid fillers) | Doctor-administered, minimally invasive wrinkle and volume treatments; identified by management as the leading non-surgical category | Women 20–40+, rising male share | Ongoing | Per-treatment and course packages (prepaid) |
| Energy-based skin treatments (e.g., photorejuvenation/IPL, picosecond laser) | Pigmentation, texture and rejuvenation; "skin management" category highlighted as popular in FY2025 | Mass-affluent urban consumers | Ongoing; new devices added in FY2023 | Course packages |
| FaceGym™ facial contouring | Facial contouring treatment upgraded in November 2022 in response to contouring demand | Younger, image-conscious clients | Upgraded Nov 2022 | — |
| Medical consultation | Doctor consultations | All clients | Ongoing | Fee per consultation (HK$3,000 of revenue in FY2025) |
| Prescription and dispensing | Medication or prescribed skincare dispensed at centres | Treatment clients | Ongoing | Per item (HK$27,000 of revenue in FY2025) |
VITAE (wellness beauty)
| Offering | Description | Target customer | Status |
|---|---|---|---|
| Wellness beauty treatments | Holistic "body, mind and soul" treatments; diversified treatment launches aimed at middle and upper-class consumers (FY2023) | Health-conscious middle/upper-class women | 2 centres (FY2025–FY2026) |
| Loyalty programme | Revamped in FY2025 to raise retention across brands | Existing clients | Revamped FY2025 |
XOVĒ (skincare)
| Product category | Description | Channel |
|---|---|---|
| Cleansers | Facial cleansing | HK stores, e-commerce, mainland platforms |
| Toners | — | Same |
| Serums | — | Same |
| Moisturisers | — | Same |
| Eye care | — | Same |
| UV protection | Sunscreen / UV defence | Same |
| Masks | — | Same |
XOVĒ is positioned as a premium line developed with Swiss skincare experts. It is designed both for daily use and as an adjunct to in-clinic treatments [press release Jun 2023; RA25]. In FY2023 it gained distribution through Sephora in Mainland China [press release Jun 2023]. Whether that arrangement continues is not publicly disclosed. Mainland revenue of HK$2.8m in FY2025 suggests the channel is now immaterial.
Financial Narrative
Miricor presents its P&L by nature of expense. It does not report gross profit, operating income or EBITDA as defined line items. The proxies below are labelled accordingly.
Income statement
Notes on the income statement:
-
Sources: [RA22], [RA23], [RA25], [FY26-S].
-
FY2026 staff, rental and PP&E depreciation figures are derived from the reported changes of −7.9%, −9.0% and −21.7% [FY26-S].
-
FY2022 and FY2023 tax figures are derived as PBT minus profit. FY2023 was a tax credit.
-
FY2021 comparatives: revenue HK$128.9m, PBT −HK$16.2m, loss HK$12.7m, EPS −3.16 cents [RA22].
Margins and EBITDA proxies (derived)
Notes on the EBITDA proxies:
-
Company-defined EBITDA is the chairlady's metric: "earnings before interest on bank loans, taxes and depreciation of PP&E" [AR25].
-
Full EBITDA = PBT + finance costs + PP&E depreciation + ROU depreciation (derived). It flatters the business because ROU depreciation is economically rent.
Revenue CAGR.
-
FY2022–FY2026: −0.1% p.a. (derived).
-
FY2021–FY2026: 23.0% p.a. (derived). This is distorted by the COVID-depressed FY2021 base.
-
FY2024–FY2026, from peak: −14.4% p.a. (derived).
Half-year profile
Notes on the half-year profile:
-
Sources: [IR Sep-2022; IR Sep-2023; IR Sep-2024]. H2 figures are derived as full year minus H1.
-
H1 FY2026 (six months to 30 Sep 2025): company headlines indicate a revenue decline and a small loss. An aggregator shows a period net loss of about HK$0.17m, but its revenue field is internally inconsistent.
Balance sheet
Notes on the balance sheet:
-
Sources: [RA22], [RA23], [IR Sep-2023 comparatives], [RA25], [FY26-S].
-
FY2023 total assets are derived from the 31 Mar 2023 balance-sheet comparatives in IR Sep-2023.
-
FY2022 and FY2023 equity are derived by rolling back FY2024 audited equity using total comprehensive income (no dividends or share issues in the period).
-
FY2021 contract liabilities were HK$168.2m.
-
No goodwill or intangibles appear on the FY2024–FY2025 balance sheets.
Cash flow
Observable facts:
-
Cash and equivalents rose HK$62.5m in FY2025 and HK$8.0m in FY2026. FY2026 also included HK$5.9m of bank-debt repayment.
-
No dividends were paid FY2022–FY2026. The first dividend cash outflow, about HK$40m, falls in FY2027 (October 2026).
-
No share repurchases occurred in FY2025 or FY2026 [RA25; FY26-S].
Ratios (derived)
Notes on the ratios:
-
ROIC is not meaningful. Invested capital is negative once contract liabilities and cash are netted.
-
Net debt/EBITDA is negative (net cash) in all verified years.
-
The cash conversion cycle is structurally misleading for a prepaid-service model. The economically relevant figure is customer prepayments of about HK$184m, which fund the business ahead of service delivery.
Commentary: trends, inflections, drivers
1. Revenue arc (FY2021–FY2026). Revenue followed a COVID trough in FY2021, a reopening boom in FY2022–FY2024, and a two-year decline (FY2025: −18.4%; FY2026: −10.1%).
-
The FY2025 fall was mostly skincare. Skincare fell HK$66.8m (−55.9%) when the mainland push was abandoned. Treatment services declined only 6.5% [RA25].
-
In FY2026 skincare fell a further 24.2% and the core treatment base fell about 8% (derived).
-
This second year of core decline is the more important signal. It tracks weak Hong Kong consumer sentiment and northbound spending by Hong Kong residents.
2. Profit inflection through cost, not growth. FY2025 operating expenses fell 24.5% [AR25]. The main moves were:
-
A&P down 60.3% (HK$65.3m → HK$25.9m);
-
staff costs down 23.0% (headcount 324 → 239);
-
rentals down 20.2%;
-
professional fees down 43.2%.
FY2026 continued the trend: staff −7.9%, rentals −9%, PP&E depreciation −21.7%, A&P −17.7%, professional fees −31.1%, credit-card commission −19.2% [FY26-S]. Net margin recovered from −2.6% (FY2024) to 3.1% (FY2026). The improvement is real but thin, and there is a limit to how far costs can be cut before service capacity suffers.
3. Tax distortion. FY2025 tax of HK$12.4m on PBT of HK$23.0m (54% effective rate) reflected the reversal of deferred tax assets [AR25]. FY2025 pre-tax earnings power was therefore stronger than net profit suggests.
4. Falling depreciation flatters FY2026. PP&E fell from HK$101.1m (FY2023) to HK$50.1m (FY2025). The resulting depreciation decline (−21.7% in FY2026) supports reported profit. It also signals under-investment relative to the FY2022–FY2023 build-out. Future device refresh capex is a monitorable.
5. Balance sheet. Cash of HK$190.3m against zero bank debt is substantial relative to a HK$300m market cap. However:
-
About HK$184m of contract liabilities represent prepaid services owed to customers.
-
Pledged deposits (about HK$66m) back credit-card and bank facilities.
-
"Free" cash is therefore considerably smaller than the headline.
6. Dividend arithmetic. The HK10-cent final dividend costs about HK$40m. That is about 3.6× FY2026 profit (payout about 357%, derived) and about 25% of FY2026 net assets. It is effectively a capital return funded from the cash pile, not a sustainable yield at current earnings.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line | Brand | Contents | Footprint (latest) |
|---|---|---|---|
Medical aesthetics | CosMax+ | Doctor-supervised non-surgical procedures: injectables (botulinum toxin, hyaluronic acid), energy-based devices (photorejuvenation, picosecond laser), facial contouring | 3 centres in Hong Kong core business districts |
Wellness beauty | VITAE | Positioned on "a balanced aesthetic experience for body, mind and soul" | 2 centres (FY2025, FY2026); 3 in FY2023 |
Skincare retail | XOVĒ | Swiss-formulated premium skincare: cleanser, toner, serum, moisturiser, eye care, UV protection, masks | 4 stores in premium HK malls (FY2026); 3 (FY2025); 10 (Mar 2023); plus e-commerce and mainland platforms |
Revenue Lines
| Revenue line (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Treatment and medical services (HKD Mn) | 289.6 | 333.5 | 374.6 | 350.3 | 322.4 |
Skincare products (HKD Mn) | 74.3 | 129.6 | 119.6 | 52.8 | 40.0 |
Total revenue (HKD Mn) | 363.9 | 463.1 | 494.3 | 403.2 | 362.4 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Treatment share of revenue (%) | 79.6 | 72.0 | 75.8 | 86.9 | 89.0 |
Skincare share of revenue (%) | 20.4 | 28.0 | 24.2 | 13.1 | 11.0 |
Treatment YoY growth (%) | — | 15.2 | 12.3 | -6.5 | -8.0 |
Skincare YoY growth (%) | — | 74.4 | -7.7 | -55.9 | -24.2 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 363.9 | 463.1 | 494.3 | 403.2 | 362.4 |
Revenue YoY growth (%) | 182.3 | 27.3 | 6.7 | -18.4 | -10.1 |
Cost of inventories and consumables (HKD Mn) | — | — | 52.8 | 50.4 | — |
Revenue less inventory cost, gross-profit proxy (HKD Mn) | — | — | 441.4 | 352.7 | — |
Staff costs (HKD Mn) | — | — | 183.8 | 141.6 | 130.4 |
Property rentals and related expenses (HKD Mn) | — | — | 67.9 | 54.2 | 49.3 |
Depreciation of PP&E (HKD Mn) | — | — | 42.4 | 35.0 | 27.4 |
Depreciation of right-of-use assets (HKD Mn) | — | — | 50.8 | 43.0 | — |
Other expenses net (HKD Mn) | — | — | 159.6 | 100.1 | — |
Finance costs (HKD Mn) | — | — | 5.2 | 5.4 | — |
Operating profit proxy, PBT plus finance costs (HKD Mn) | — | — | -6.6 | 28.4 | — |
Profit before tax (HKD Mn) | 31.2 | -23.9 | -11.8 | 23.0 | — |
Income tax expense (HKD Mn) | 5.8 | -3.4 | 0.8 | 12.4 | — |
Net profit attributable (HKD Mn) | 25.4 | -20.5 | -12.6 | 10.6 | 11.2 |
Basic EPS (HK cents) | 6.35 | -5.13 | -3.15 | 2.65 | 2.81 |
Diluted EPS (HK cents) | 6.35 | -5.13 | -3.15 | 2.65 | 2.81 |
Dividend per share (HK cents) | 0 | 0 | 0 | 0 | 10 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%) and Income Statement
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin proxy (%) | — | — | 89.3 | 87.5 | — |
Operating margin proxy (%) | — | — | -1.3 | 7.0 | — |
PBT margin (%) | 8.6 | -5.2 | -2.4 | 5.7 | — |
Net margin (%) | 7.0 | -4.4 | -2.6 | 2.6 | 3.1 |
Company-defined EBITDA excl. ROU depreciation (HKD Mn) | — | — | 31.7 | 58.6 | — |
Full EBITDA incl. ROU depreciation, post-HKFRS 16 (HKD Mn) | — | — | 86.6 | 106.4 | — |
Full EBITDA margin (%) | — | — | 17.5 | 26.4 | — |
Income Statement
| Metric | H1FY2022 | H2FY2022 | H1FY2023 | H2FY2023 | H1FY2024 | H2FY2024 | H1FY2025 | H2FY2025 |
|---|---|---|---|---|---|---|---|---|
Revenue (HKD Mn) | 199.7 | 164.2 | 211.9 | 251.2 | 237.0 | 257.3 | 200.1 | 203.1 |
Net profit (HKD Mn) | 53.9 | -28.5 | 3.4 | -23.9 | -13.1 | 0.4 | -0.6 | 11.2 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | — | 516.8 | 479.4 | 471.3 | — |
Cash and cash equivalents (HKD Mn) | — | 116.9 | 119.8 | 182.3 | 190.3 |
Pledged time deposits (HKD Mn) | — | 62.4 | 62.6 | 65.8 | — |
Interest-bearing bank borrowings, all current (HKD Mn) | — | — | 12.5 | 5.9 | 0.0 |
Lease liabilities total (HKD Mn) | — | — | 87.2 | 82.9 | — |
Net cash excl. leases and pledged deposits (HKD Mn) | — | — | 107.3 | 176.5 | 190.3 |
Contract liabilities and deferred revenue (HKD Mn) | 130.2 | 182.0 | 183.0 | 183.7 | — |
Inventories (HKD Mn) | — | 38.2 | 42.2 | 35.5 | — |
Property plant and equipment (HKD Mn) | — | 101.1 | 85.8 | 50.1 | — |
Right-of-use assets (HKD Mn) | — | 109.3 | 83.1 | 78.5 | — |
Goodwill and intangibles (HKD Mn) | — | — | 0 | 0 | — |
Net current assets / working capital (HKD Mn) | — | — | 4.6 | 51.1 | — |
Total equity (HKD Mn) | 171.3 | 150.7 | 136.8 | 147.6 | 158.3 |
Key Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Change in cash and equivalents (HKD Mn) | — | — | 2.9 | 62.5 | 8.0 |
Dividends paid (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 16.0 | -12.7 | -8.8 | 7.4 | 7.3 |
ROA on average assets (%) | — | — | -2.5 | 2.2 | — |
Current ratio (x) | — | — | 1.02 | 1.19 | — |
Bank debt to equity, company gearing (%) | — | — | 9.1 | 4.0 | 0.0 |
Interest coverage, operating proxy / finance costs (x) | — | — | -1.3 | 5.3 | — |
Asset turnover (x) | — | — | 0.99 | 0.85 | — |
Inventory days on cost of inventories (days) | — | — | 291 | 257 | — |
Receivable days (days) | — | — | 9.9 | 3.5 | — |
Payable days (days) | — | — | 73 | 46 | — |
Cash conversion cycle (days) | — | — | 228 | 215 | — |
Revenue by Region and Revenue by Region (%)
| Region (HKD Mn) | FY2024 | FY2025 |
|---|---|---|
Hong Kong revenue (HKD Mn) | 450.8 | 400.3 |
Mainland China revenue (HKD Mn) | 43.4 | 2.8 |
Hong Kong share of revenue (%) | 91.2 | 99.3 |
Share Price History
| Date | Price (HKD) | Context | Source |
|---|---|---|---|
10 Jan 2017 | 0.80 | IPO price | etnet |
Jun 2024 (approx.) | 1.14 | Last-trade snapshot | TradingView |
23–26 Jun 2026 | 0.68 | Pre-FY2026 results | lixinger |
30 Jun 2026 | 0.91 | Post dividend announcement | lixinger |
2–10 Jul 2026 | 0.90 | — | lixinger, etnet |
14–16 Jul 2026 | 0.72–0.73 | Thin trading | lixinger |
17–24 Jul 2026 | 0.89 | — | lixinger |
27 Jul 2026 | 0.73 | — | lixinger |
31 Jul – 3 Aug 2026 | 0.75 | Latest verified quote | etnet |
Valuation Multiples
| Multiple | Miricor | Notes |
|---|---|---|
Market cap (HKD Mn) | 300 | 400m shares |
P/E trailing (x) | 26.7 | EPS HK2.81 cents |
P/B (x) | 1.90 | Net assets HK$158.3m |
EV (HKD Mn) | 110 | Market cap less cash HK$190.3m; excludes leases and pledged deposits |
EV/Sales (x) | 0.30 | — |
EV / company-defined EBITDA, FY2025 (x) | 1.9 | HK$58.6m |
Dividend yield (%) | 13.3 | HK10 cents, likely non-recurring at this level |
P/S (x) | 0.83 | — |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (HK cents) | 0 | 0 | 0 | 0 | 10 |
Payout ratio (%) | 0 | 0 | 0 | 0 | 357 |
Analyst Conclusions
Management guidance. There is no quantitative guidance. Qualitative stance [AR25; FY26-S]:
-
a "prudent and steady" operating strategy;
-
expectation of steady market growth in Hong Kong aesthetics;
-
expectation that regulation will consolidate share toward compliant operators;
-
continued digital investment and equipment upgrades;
-
continued cost discipline.
Consensus. None.
Bull case
-
Cash-backed downside. EV of only about HK$110m against company-defined EBITDA of HK$58.6m (FY2025) implies about 2× EV/EBITDA for a debt-free business with HK$184m of customer prepayments. The HK10-cent dividend signals the controlling shareholder's willingness to return capital.
-
Operating leverage. After about HK$90m of annual cost removal between FY2024 and FY2026, any stabilisation of the HK$320–350m treatment base would lift margins sharply.
-
Regulatory moat. Device and practitioner rules raise the bar. A doctor-led chain with a former Director of Health on the board could gain share or acquire distressed clinics with its cash.
Bear case
-
Structural shrinkage. Treatment revenue fell in both FY2025 (−6.5%) and FY2026 (about −8%). Cost cuts cannot offset indefinitely, and falling depreciation partly reflects under-investment.
-
Overstated "free" cash. About HK$184m of contract liabilities and about HK$66m of pledged deposits mean economically unencumbered cash is far smaller than HK$190m. A HK$40m dividend at 3.6× earnings is not repeatable.
-
Governance and liquidity discount. Combined Chair/CEO, about 69% founder control, no coverage, and a sub-HK$0.5m daily turnover profile. INED tenure has also reached the nine-year threshold. Together these limit any re-rating.
Key catalysts and monitorables (next 12 months)
| Item | Timing |
|---|---|
| Dividend payment and any guidance on future payouts | 23 Oct 2026 |
| H1 FY2027 interim results (treatment revenue trend, contract-liability balance) | Late Nov 2026 |
| Use of share repurchase mandate | Ongoing |
| Board refresh and INED replacements | FY2027 |
| Hong Kong medical-device regulation implementation milestones | 2026–2027 |
| XOVĒ store count and omni-channel results | FY2027 |
| Capex / device refresh versus depreciation | FY2027 accounts |
| FY2027 results and dividend decision | Jun 2027 |
Analyst verdict
Miricor is a founder-controlled Hong Kong clinic operator that has traded growth for survival, and survival for solvency. The FY2023–FY2024 attempt to turn the company into a skincare-plus-mainland platform failed decisively:
-
record revenue of HK$494m was accompanied by losses;
-
mainland sales collapsed from HK$43m to under HK$3m within a year.
Management deserves credit for the speed and scale of the subsequent restructuring:
-
operating expenses down a quarter in a single year;
-
headcount down by a quarter;
-
bank debt eliminated;
-
two consecutive years of modest profit (HK$10.6m and HK$11.2m).
The resulting balance sheet, with HK$190m of cash and no borrowings, is the stock's defining feature and underpins a superficially compelling valuation of about 0.3× EV/Sales.
That valuation is cheaper than it looks, for three reasons:
-
Customer prepayments. Much of the cash is customers' money: contract liabilities of about HK$184m are services still owed.
-
Shrinking core. Two years of decline in treatment revenue show the issue is not just skincare.
-
Non-recurring dividend. The headline 13% yield rests on a payout roughly 3.6 times earnings. It is better read as a one-off capital return by a 69% holder than as a durable income stream.
Net margins around 3% compare poorly with Perfect Medical's high-teens. This suggests sub-scale economics that cost-cutting alone cannot fix.
The investment debate therefore turns on whether Hong Kong's regulatory tightening produces genuine share consolidation that a compliant, cash-rich, doctor-governed chain can capture, organically or by acquisition. The alternative is a continued slow leak of customers to cheaper cross-border and boutique competitors.
Until the treatment-revenue line stabilises and management articulates a capital-allocation framework, Miricor is best characterised as a special-situation, balance-sheet-supported micro-cap. Its upside depends on capital returns and a regulatory catalyst, not on a growth franchise. Investors should treat it as a liquidity-constrained position, sized accordingly, with the H1 FY2027 contract-liability balance and treatment revenue as the key tells.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Age (AR25) | Background / education |
|---|---|---|---|---|
Ms. LAI Ka Yee Gigi (黎珈而, formerly Lai Chi, "Gigi Lai") | Executive Director, Chairlady and CEO; Chair of Nomination Committee; member of Remuneration Committee | Joined Jul 2009; Director 6 Jul 2016; Chair/CEO 19 Dec 2016 | 53 (54 per 2026 AR) | Film and TV actress 1985–2008; founder; responsible for overall management, branding, strategy and marketing |
Mr. HO Tsz Leung Lincoln (何子亮) | Executive Director; Chief Operating Officer | Joined Jul 2019 as Chief Brand Officer; ED 22 Apr 2020; COO May 2020 | 49 | Neo Derm Group 2006–2016 and 2017–2019 (marketing communications and digital marketing director); Airport Authority HK (2016); BTL Hong Kong (regional marketing director); DDB, Leo Burnett; BA Design, HK PolyU (2002); 2005 HK Film Awards nominee |
Dr. LAM Ping Yan (林秉恩), SBS | Executive Director | Jul 2020 | 73 | Director of Health, HKSAR 2003–2012 (led SARS and swine-flu responses); MBBS HKU (1977); MMed Public Health NUS (1992); FHKAM; former member of Medical Council of HK and Hospital Authority Board |
Mr. CHENG Yuk Wo (鄭毓和) | INED; Chair of Audit and Remuneration Committees | 19 Dec 2016 | 64 | Chartered accountant (ICAEW, HKICPA, CPA Canada); MSc LSE; INED of CSI Properties, Liu Chong Hing Investment, Chia Tai Enterprises, Somerley Capital, Kidsland |
Mr. CHENG Fu Kwok David (鄭輔國) | INED; Audit and Nomination Committees | 19 Dec 2016 | 76 | Former Head of Shipfinance, Crédit Agricole CIB; Chevalier de l'Ordre National du Mérite (2015); BSocSc HKU |
Mr. LI Wai Kwan (李偉君) | INED; Audit and Remuneration Committees | 19 Dec 2016 | 53 | CFO of Crystal International Group (2232.HK) since Nov 2018; formerly Esprit, COFCO; CFA, FCCA, FCA; BCom Toronto, MBA Schulich |
Major Shareholders
| Holder | Shares | % | Basis |
|---|---|---|---|
Sunny Bright Group Holdings Ltd (BVI), beneficially associated with Ms. Lai Ka Yee Gigi and spouse Mr. Ma Ting Keung (馬廷強) | 275,000,000 | 68.75 | etnet SDI data (30 Sep 2024); listing documents |
Meitu, Inc. (1357.HK) | about 20,000,000 (implied) | 5.0 | Newswire brief of an HKEX filing that Meitu's long position "rose to 5.0%". |
Public float | about 125,000,000 | about 31.25 | Derived |
Shareholding by CCASS Participant
| CCASS participant | Shares (m) | % |
|---|---|---|
Bank of East Asia (custodian of the controlling block) | 275.0 | 68.75 |
Bright Smart Securities | 37.7 | 9.42 |
UOB Kay Hian (HK) | 20.0 | 5.00 |
UBS | 19.4 | 4.85 |
BOCI Securities | 11.0 | 2.74 |
華晉證券資產管理 | 7.0 | 1.74 |
威華達證券 | 6.1 | 1.53 |
Competitive Landscape
Key Competitors
| Competitor | Listing | Positioning vs Miricor | Latest revenue | Source |
|---|---|---|---|---|
Perfect Medical Health Management | 1830.HK | Largest listed HK medical-beauty chain; multi-brand; 100%+ payout policy | HK$962.3m (FY3/2026, −14.7%); profit HK$178.3m | Perfect Medical results announcement, 30 Jun 2026 |
Water Oasis Group (Oasis Medical, Oasis Beauty, Glycel, Eurobeauté, AesMedic) | 1161.HK | Integrated beauty services and products; 9 Oasis Medical centres | About HK$981m (FY9/2025); earnings about HK$81m | Water Oasis AR 2025; stockanalysis.com (secondary) |
EC Healthcare (medical aesthetics within a broader healthcare platform) | 2138.HK | Scale player, medical-led | — | — |
Neo Derm Group | Private | Medical aesthetics chain; COO Ho's former employer | — | — |
DR Reborn | Private | Mass-premium beauty/aesthetics chain | — | — |
Modern Beauty Salon | — | Beauty salons/spa | — | — |
Independent doctor-led aesthetic clinics | Private | Fragmented long tail; price competitors | — | — |
Mainland "northbound" aesthetics (Shenzhen clinics) | Various | Cheaper treatments for HK residents crossing the border | Not quantified | — |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Miricor (FY3/2026) | Perfect Medical (FY3/2026) | Water Oasis (FY9/2025) |
|---|---|---|---|
Revenue (HKD Mn) | 362.4 | 962.3 | 981.3 |
Revenue growth YoY (%) | -10.1 | -14.7 | -0.2 |
Net profit (HKD Mn) | 11.2 | 178.3 | 81.3 |
Net margin (%) | 3.1 | 18.5 | 8.3 |
Dividend payout (%) | 357 | 102.8 | — |
Miricor revenue as % of peer (%) | 100 | 37.7 | 36.9 |



